Biography:
Dr. Doverskog has a MSc and PhD in biotechnology from the Royal Institute of Technology, Stockholm and an Executive MBA from Stockholm Business School. Magnus is presently SVP & Chief Scientific Officer at Umecrine Cognition, a biotechnology company located at Karolinska Institute Science Park, Stockholm with > 20 years industry experience from development of small molecules and biologics. Senior positions at Astra Pain Control, Biovitrum AB, and as CEO of IMED AB. Post-doc at European Molecular Biology Laboratory (EMBL) in Heidelberg with a Marie Curie individual Fellowship. Magnus was the CEO of Umecrine Cognition between 2012-2022.
Title : Golexanolone, a GABAA receptor-modulating steroid antagonist, improves microglia activation and tyrosine hydroxylase levels in substantia nigra, dopamine in striatum and several motor and non-motor alterations in 6-OHDA rats